Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

This study has been completed.
Cell Pathways
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: May 8, 2002
Last updated: October 14, 2011
Last verified: October 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2003
  Estimated Primary Completion Date: No date given